[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

The irreversible ERBB1/2/4 inhibitor neratinib has been shown in vitro to rapidly reduce the expression of ERBB1/2/4 and RAS proteins via autophagic/lysosomal degradation. We have recently demonstrated that neratinib and valproate interact to suppress the growth of 4T1 mammary tumors but had not def...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Kirkwood, John, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814195/
https://www.ncbi.nlm.nih.gov/pubmed/29464055
http://dx.doi.org/10.18632/oncotarget.23681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814195/
https://www.ncbi.nlm.nih.gov/pubmed/29464055
http://dx.doi.org/10.18632/oncotarget.23681

Ejemplares similares